Abiraterone is under clinical development by Austhera BioSciences and currently in Phase II for Hormone-Sensitive Prostate Cancer.

PAX-1 is under clinical development by Komipharm International and currently in Phase I for Head And Neck Cancer.

Ofer Gofrit, head of the urology department at Jerusalem’s Hadassah Medical Center, said in a video statement late Sunday ...

Women are up to two times more likely to test for cancer than men, a discounted screening promotional offer by the AAR Hospital has indicated ...

Datamining can mean exploiting information for profit but two new South Carolina databases allow the public to look at health ...

Israeli Prime Minister Benjamin Netanyahu underwent successful surgery Sunday to have his prostate removed, hospital ...